Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

This activity is supported by independent educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seagen, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on January 30, 2024 and is valid until January 30, 2025. Requests for credit must be made no later than January 30, 2025.

TARGET AUDIENCE

The primary target audience for this activity are Hematology-oncologists, pediatric hematologists/oncologists, hematologists, nurse practitioners, physician assistants, medical oncologists, oncology pharmacists, and other health care providers (HCPs) involved in the care of patients with Hodgkin lymphoma.

STATEMENT OF NEED/PROGRAM OVERVIEW

While rare in the pediatric population, Hodgkin lymphoma (HL) constitutes approximately 40% of all lymphomas that present during childhood and is the most common malignancy in adolescents and young adults. Pediatric HL is highly sensitive to treatments for adults, but long-term toxicity is worse in developing individuals. Therefore, ongoing clinical trials for pediatric HL are attempting to reduce long-term toxicity and increase efficacy.

Join a panel of hematologists and oncologists to review available treatment options and receive practical guidance on the management of young patients with HL. Experts will discuss regimen selection, the management of complications, and the unique treatment challenges associated with managing pediatric and young-adult populations. Clinicians will be brought up to date with the latest evidence across all aspects of care to make informed and confident management decisions and achieve long-term treatment goals.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Review the efficacy and safety of current and emerging therapeutic regimens for pediatric and young-adult patients with Hodgkin lymphoma in the frontline and relapsed/ refractory settings
• Identify best practices for the proactive identification and management of adverse events associated with current and emerging therapeutic regimens
• Discuss multidisciplinary approaches to survivorship and follow-up care plans for pediatric and young-adult patients with Hodgkin lymphoma

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty	Conflicts of Interest
Lisa Giulino Roth, MD Director, Pediatric Oncology Director, Adolescent and Young Adult Lymphoma Program Weill Cornell Medical College Vice Chair, Hodgkin Lymphoma Committee, Children’s Oncology Group	Dr. Lisa Roth, faculty for this educational activity, has the following relevant financial relationships: • Consultant, Advisor, Speaker: Merck & Co. • Researcher: Seagen, Inc.
Matthew Ehrhardt, MD, MS Associate Member, Department of Oncology St. Jude Children's Research Hospital	Dr. Matthew Ehrhardt, faculty for this educational activity, has no relevant financial relationships.
Elizabeth Stone Refractory Hodgkin's Lymphoma patient	Elizabeth Stone, a vignette speaker for this activity, has no relevant financial relationships.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.